EP0562014A1 - Methods for labelling oligonucleotides - Google Patents

Methods for labelling oligonucleotides

Info

Publication number
EP0562014A1
EP0562014A1 EP92902929A EP92902929A EP0562014A1 EP 0562014 A1 EP0562014 A1 EP 0562014A1 EP 92902929 A EP92902929 A EP 92902929A EP 92902929 A EP92902929 A EP 92902929A EP 0562014 A1 EP0562014 A1 EP 0562014A1
Authority
EP
European Patent Office
Prior art keywords
nucleotide
group
terminus
sugar
sugar residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92902929A
Other languages
German (de)
French (fr)
Other versions
EP0562014A4 (en
Inventor
Clifford M. Chan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP0562014A1 publication Critical patent/EP0562014A1/en
Publication of EP0562014A4 publication Critical patent/EP0562014A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Definitions

  • This invention relates to the covalent coupling of detectable marker molecules into nucleic acid segments referred to as oligonucleotides. More specifically, it relates to 5' end labelling of oligonucleotides wherein each oligonucleotide contains only one marker molecule.
  • BACKGROUND Labelled oligonucleotides find utility in a number of applications, including DNA sequencing, diagnostic detection or quantitation and forensic science.
  • the labelled oligonucleotide is allowed to hybridize or anneal with nucleic acid present in the sample and the presence or absence of label is detected following separation steps.
  • Many mechanisms and schemes have been used to introduce labels into oligonucleotides. For a comprehensive review of these methods see Goodchild, - Bioconjugate Chemistry, 1(3) .165-187 (1990). According to Goodchild, past researchers have labelled oligonucleotides at both internal and terminal locations; by enzymatic and chemical synthetic means; and utilizing a single or many marker molecules per oligonucleotide.
  • Methods involving incorporation of marker moieties at internal locations in the oligonucleotides are generally less preferable due to their less predictable hybridization behavior; end- labelled oligonucleotides are preferred, particularly for automated detection systems.
  • methods for incorporating multiple label moieties into an oligonucleotide are less preferred for stoichiometric reasons. Labelling methods which randomly insert radiolabelled or haptenated bases into the oligonucleotide produce a labelled probe which is more difficult to quantitate. The correlation of signal generated to the amount of probe present is not straightforward.
  • labelled oligonucleotides are poorly characterized in terms of exact positioning and number of label molecules.
  • each oligonucleotide have a single marker moiety at an end location.
  • Methods for placing a single marker, or hapten capable of reacting with an antibody or other specific binding member, at a terminal position on an oligonucleotide have been described in the literature.
  • a linker member containing a primary amine or other nucleophilic group is attached at an available hydroxyl to enable conjugation to one of numerous electrophilic detectable markers.
  • terminal deoxynucleotidyl transferase, ligase and phosphoramidite chemistry have been used to attach direct labels or reactive linkers to oligonucleotides.
  • Ke pe, et al. Nucleic Acids Research 13(1) :45 (1985) describe biotinylation of the 5' end of synthesized oligonucleotides.
  • an aminoethanol derivative of biotin is condensed with a polymer supported derivatized nucleotide. After the reaction and deprotection, a phosphodiester bond connects the animoethanol-biotin to the nucleoside at the 5' hydroxyl.
  • 5' amino deoxythymidine nucleotide The 5' amino group is first protected and a phosphoramidite is prepared, which is then used as a final step to add the aminated base to the 5' hydroxyl of the synthesized chain. After cleavage and deprotection, the amino group can be reacted with a number of different electrophilic fluorophores to generate a 5' labelled oligonucleotide.
  • the present invention seeks to overcome the problems associated with prior methods, and to provide a method for end labelling of oligonucleotides which is amenable to automation and versatile enough to be useful for the addition of any one of many different markers, without the need to prepare specialized reagents for each marker.
  • the invention also eliminates the spacer arms between the 5' carbon of the sugar residue and the marker molecule.
  • the invention relates to a method for labeling the 5' end of a nucleotide synthesized on a solid support so as to have a free hydroxyl at the 5' terminal carbon of the nucleotide sugar residue, the method comprising: a. reacting the 5' terminus of the nucleotide sugar residue with a reactant member to produce an activated 5' terminus having a leaving group attached thereto; b. reacting the activated 5' terminus with a marker molecule containing a nucleophilic group to displace the leaving group and covalently attach the marker molecule to the 5' carbon of the nucleotide sugar residue; and c. cleaving the labeled nucleotide from the solid phase.
  • the reactant member is a sulfonyl chloride and the nucleophilic group is selected from the group consisting of amines, thiols and alcohols.
  • the most preferred nucleophilic group is amine.
  • Preferred marker moieties are haptens.
  • the invention relates to nucleotides labeled at their 5' end by the above process.
  • Nucleotides according to the invention have the following general structure: B - Sugar-CH - N ' -MM
  • B represents a base selected from the group consisting of adenine, cytosine, guanine, thymine, uracil, and analog derivatives thereof;
  • Sugar represents ribose, deoxyribose or analogs thereof;
  • CH. is the methylene group at the 5' terminus of the sugar residue;
  • MM represents a marker molecule;
  • N' represents a nucleophilic group of the marker molecule;
  • Rem is attached to the sugar residue at its 3' carbon and represents OH, a phosphodiester linkage to a second nucleotide, or a spacer connected to a solid support.
  • the invention relates to intermediates useful for labelling the 5' end of an oligonucleotide.
  • Intermediates have the following general structure: B - - LG wherein B represents a base selected from the group
  • adenine cytosine, guanine, thymine, uracil, and analog derivatives thereof
  • Sugar represents ribose, deoxyribose or analogs thereof
  • CH_ is the methylene group at the 5' terminus of the sugar residue
  • LG represents a leaving group which can be displaced by a nucleophile
  • Rem is attached to the sugar residue at its 3' carbon and represents OH, a phosphodiester linkage to a second nucleotide, or a spacer connected to a solid support.
  • Exemplary leaving groups include aromatic or aliphatic sulfonates, eg. tosylates or esylates.
  • the invention is a novel method for labelling the 5' end of an oligonucleotide synthesized on a solid support.
  • the method comprises removing the 5' hydroxyl and activating the 5' carbon with a reactant member capable of exchanging the hydroxyl for a good leaving group; followed by reaction of the activated 5' terminus with a nucleophilic group of a marker molecule.
  • solid support Essentially the only requirement of the solid support is that it have a functionalized or derivatized group available for reacting with the 3' terminus of a nucleotide.
  • Such solid supports include those which are already derivatized with the first nucleotide, and those which are merely functionalized for the incorporation of the first nucleotide in the chain.
  • Typical solid supports include controlled pore glass (CPG), silica gel and polymer-based resins.
  • CPG supports are commercially available from Clontech (Palo Alto, CA) and CPG, Inc. (Fairfield, NJ) both with and without the first nucleotide attached.
  • Functionalized solid supports are available with short chain and long chain amino groups as the functional group.
  • the long chain aminated CPG supports are presently preferred.
  • the reactant member is a reagent capable of exchanging the hydroxyl at the 5' carbon for a "good leaving group".
  • Good leaving groups are well known to those of skill in the art. They are characterized by their electron density which renders them easily displaced by a nucleophile in a substitution reaction generally known as SN2.
  • Reactant members must satisfy two criteria: they must include an "R” group which comprises a "good leaving group”; and they must be sufficiently reactive to displace the 5' hydroxyl and exchange the leaving group in its place. Exemplary and preferred reactant members are described below.
  • a preferred reactant member is an aromatic or aliphatic sulfonyl halide having the general structure:
  • R - SO. - X where R is an aromatic or aliphatic group and X is a halide, preferably Cl or Br.
  • aromatic refers to substituted or unsubstituted ring structures generally
  • Preferred aromatic sulfonyl halide reactant members include p-toluenesulfonyl chloride (to ⁇ yl chloride) p- bromobenzenesulfonyl chloride (brosyl chloride) and p- nitrobenzenesulfonyl chloride (nosyl chloride).
  • the R group of the sulfonyl halide reactant members may also be aliphatic.
  • the term "aliphatic" includes groups which may be straight or branched, preferably straight; and ideally no longer than eight backbone atoms total. Alkyl chains having less than about 8 carbons, preferably less than 4, are preferred aliphatic groups for sulfonyl halide reactant members.
  • Both aliphatic and alkyl R groups may include substitutions provided they do not interfere with the criteria of the reactant member. Certain substitutions are useful to enhance the reactant members ability to serve as a leaving group.
  • Exemplary aliphatic reactant members are methanesulfonyl chloride, trifluoromethane sulfonyl chloride, ethanesulfonyl chloride, ' 2,2,2 trifluoroethanesulfonyl chloride, propanesulfonyl chloride, and ammonioalkane sulfonyl halides.
  • reactant members have largely been sulfonyl chlorides, it will be recognized by one of ordinary skill in the art that other halides may also be used.
  • sulfonic acid bromides will function as reactant members in the present invention, when reaction conditions are appropriately modified.
  • reactant members equivalent to the sulfonyl halides include any reactant member which bears a suitable "leaving group" and can be made to displace the 5' hydroxyl. It is also possible to utilize a combination of two or more reagents as reactant members. For example, one can convert the 5' hydroxyl to a bromide leaving group using carbontetrahalides and triphenylphosphine.
  • the marker molecule employed in the labelling step can be selected from a wide variety of such compounds having nucleophilic groups.
  • the term "marker molecule” is intended to include at least the following 3 classes of molecules:
  • molecules that are capable of directly providing a detectable signal such as radioactive molecules and chemiluminescent molecules
  • hooks are one member of a pair of specific binding partners, such as haptens (bind to antibodies) and biotin (binds to avidin or antibody) .
  • marker molecules which fall into the third category; and particularly preferred to utilize small molecular weight haptens.
  • haptens are generally known to those skilled in the art and include, without limitation, biotin, iminobiotin, fluorescein, dansyl, acridine, dinitrophenol, dibenzofuran, luminols (eg. N-4-aminobutyl-N-ethyl isoluminol - ABEI).
  • Other useful marker molecules include fluorophores, such as fluorescein and rhodamine; and chemilumiphores, such as acridine and luminols.
  • Nucleophilic groups useful in the invention include amines, thiols and alcohols, although other nucleophilic groups may be deemed equivalent. Generally, the stronger the nucleophile, the weaker the leaving group may be in terms of its "leaving" ability. Thus, stronger nucleophilic groups would generally be preferred over weaker ones, so that a greater range of leaving groups and reactant members may be employed. However, for reasons of stability and ease of synthesis, the preferred nucleophilic group for the present invention is amines. Primary nucleophilic groups are typically preferred over secondary or tertiary groups. The nucleophilic group found most commonly and most readily available in a plurality of marker moieties is an amino group, preferably a primary amino group.
  • reaction conditions under which the nucleophilic group of the marker molecule will react with the activated 5' terminus are well known to those of ordinary skill in the art. Because this reaction is believed to be a nucleophilic displacement, standard textbooks (See for example March, J., supra) give the reaction conditions under which the nucleophilic group will react with the activated 5' terminus to displace the leaving group and covalently bond the marker molecule directly to the 5' carbon of the sugar residue. Variations on these reaction conditions are well within the ability of the routine practitioner.
  • oligonucleotide is cleaving the oligonucleotide from the solid support.
  • the Applied Biosystems 380B synthesizer generally employs concentrated ammonium hydroxide to separate the oligonucleotide from the support.
  • Other available methods include strong sodium hydroxide and ethanolic 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU - Aldrich Chemical, Milwaukee, WI) .
  • Labelled oligonucleotides prepared according to this invention have utility in a number of diagnostic applications. For example, Whitely, et al., U.S.
  • 4,883,750 describe a diagnostic method in which a diagnostic probe and a contiguous probe are laid down on a target strand and are ligated together. The ligated product is then detected. Incorporation of a marker molecule at the 5 ' end of the probe whose 3' end undergoes ligation would permit rapid detection of the ligated product.
  • LCR ligase chain reaction
  • oligodeoxynucleotide was synthesized using phosphoramidite chemistry on an ABI 380A automated DNA synthesizer according to standard instrument procedure.
  • a 1 /xmole scale protocol modified to increase reaction time, was used to synthesize a 16 mer.
  • the sequence was regularly alternating bases, although it is believed that the specific sequence is immaterial to the invention.
  • the synthesis was programmed with 5' dimethoxytrityl protection off ("DMT-off", see ABI 380A operator manual) while the protected oligonucleotide remained attached to the control pore glass.
  • DMT-off dimethoxytrityl protection off
  • toluenesulfonyl chloride (Aldrich Chemical, Milwaukee, WI) freshly prepared in dry pyridine was attached to one end of the column via a luer tip. An empty syringe was mounted on the opposite end to receive the eluate. The 0.1M p-toluenesulfonyl chloride solution was carefully passed through the column five times, followed by incubation at 55°C for an additional 24 hours. The excess p-toluenesulfonyl chloride solution was removed and the column was washed with 10 ml of dry acetonitrile.
  • ABEI N-4-Aminobutyl-N-ethyl isoluminol
  • DMF dry dimethylformamide
  • EXAMPLE 2 Preparation of a 5' Labelled Oligonucleotide Using Methanesulfonyl Chloride
  • An oligodeoxynucleotide was synthesized using phosphoramidite chemistry on an ABI 380A automated DNA synthesizer according to standard instrument procedure.
  • a 1 /.mole scale protocol modified to increase the reaction time, was used to synthesize a second 16 mer.
  • the sequence was a single base repeated although it is believed that the specific sequence is immaterial to the invention.
  • the synthesis was programmed with 5' dimethoxytrityl protection off ( "DMT- off", see ABI 380A operator manual) while the protected oligonucleotide remained attached to the control pore glass.
  • the column was removed from the synthesizer.
  • a 10 ml syringe filled with 5 ml of 0.1M solution methanesulfonyl chloride (Aldrich Chemical, Milwaukee, WI) freshly prepared in dry pyridine was attached to one end of the column via a luer tip.
  • An empty syringe was mounted on the opposite end to receive the eluate.
  • the 0.1M methanesulfonyl chloride solution was carefully passed through the column several times, followed by incubation at 25°C for an additional 24 hours. The excess methanesulfonyl chloride solution was removed and the column was washed with 10 ml of dry acetonitrile.
  • ABEI a hapten and chemilumiphore
  • DMF dry dimethylformamide
  • the 5' labelled DNA was removed from the CPG with the treatment of concentrated NH 4OH for 1 hour under standard. Applied Biosystem Inc. protocols (ABI 380A DNA synthesizer user manual). The 5' labelled oligonucleotide was heated at 55°C overnight to remove the protecting groups from the protected bases. Evaporation of NH 4 0H gave crude 5' labelled oligonucleotides.
  • UV/VIS spectra The 5' ABEI-labelled oligonucleotide band and the control oligonucleotide band were extracted from the polyacrylamide gel and assayed with UV/VIS spectroscopy. In both cases, the spectra indicated an absorption peak at 327nm (for ABEI) along with the absorption peak at 260nm (characteristic of DNA).
  • chemiluminescence One ⁇ L of the 5' ABEI labelled oligonucleotide from Example 1 was added to a TD * (Abbott Laboratories, Abbott Park, IL) cuvette containing 100 ⁇ L of distilled water. Then 100 ⁇ l> of 0.3 mg/ml Vanadium IV catalyst was added and the cuvette was placed inside a chemiluminometer (Abbott Laboratories, IL; although any commercial chemiluminometer will suffice). 200 ⁇ L of 3% hydrogen peroxide in 0.25 N NaOH solution was injected into the cuvette and the emitted light was measured for 5 seconds immediately after the injection.
  • TD * Abbott Laboratories, Abbott Park, IL
  • Example 1 is repeated except aminomethylfluorescein (AMF: See U.S. Patent 4,510,251, Abbott Laboratories) is used instead of the ABEI reagent.
  • AMF aminomethylfluorescein
  • the conditions are the same as in Example 1, but for the marker reagent.
  • Evaluation of this labelled oligonucleotide is done using electrophoresis and/or UV/VIS spectroscopy.
  • the AMF labelled oligonucleotide will have an absorption peak at about 495 nm, in addition to the characteristic DNA peak at 260 nm.
  • Example 2 is repeated except that 0.1M p- nitrobenzenesulfonyl chloride is used in place of the 0.1M methanesulfonyl chloride. Other conditions and steps remain the same except the reaction times may take a little longer at 25°. Performing the reactions at a higher temperature should decrease the reaction times.
  • Example 2 is repeated except a solution consisting of carbontetrachloride and triphenylphosphine in acetonitrile, each 0.1M, is used in place of 0.1M methanesulfonyl chloride.
  • the result is a 5'-chloro activated derivative which is reacted with a nucleophilic marker molecule under conditions as in example 2 to label the oligonucleotide.
  • EXAMPLE 7 Preparation of a 5' Labelled Oligonucleotide via a 5'-bromo leaving group
  • Example 2 is repeated except a solution consisting of carbontetrabromide and triphenylphosphine in acetonitrile, each 0.1M, is used in place of 0.1M methanesulfonyl chloride.
  • the result is a 5'-bromo activated derivative which is reacted with a nucleophilic marker molecule under conditions as in example 2 to label the oligonucleotide.
  • EXAMPLE 8 Preparation of a 5' Labelled Oligonucleotide via a 5' activation with Mitsunobu reagent
  • Example 2 is repeated except the syringe at a first end of the column contains a solution (0.1M, 5ml) consisting of triphenylphosphine and 3-hydroxy- dibenzofuran (a hapten) in acetonitrile.
  • the syringe attached to the other end of the column contains a solution (0.1M, 5ml) of diethylazodicarboxylate in acetonitrile.
  • the two solutions are passed alternately through the column to acheive adequate mixing and the column is incubated at 25°C for 24 hours.
  • the excess reagent is removed and the column is washed with acetonitrile (20ml).
  • the result is a dibenzofuran-labeled oligonucleotide (at the 5' end) and removal of the labeled oligonucleotide proceeds as in example 2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Procédé permettant de marquer le terminal 5' d'un nucléotide synthétisé sur un support solide. Dans ce procédé, on fait réagir la terminaison libre 5' hydroxyle avec un élément réactif choisi pour activer le terminal 5', on fait réagir la terminaison 5' activée avec une molécule de marqueur contenant un groupe nucléophile, et on effectue le clivage du nucléotide marqué provenant de la phase solide. Cette invention concerne également des nucléotides marqués au niveau de leur terminaison 5' à l'aide du procédé décrit ci-dessus, dans lequel le groupe nucléophile de la fraction de molécule de marqueur est lié de manière covalente directement au carbone 5'; ainsi que des produits intermédiaires de nucléotides comprenant des terminaisons 5' activées.Method for labeling the 5 ′ terminal of a nucleotide synthesized on a solid support. In this method, the free 5 'hydroxyl terminus is reacted with a reactive element chosen to activate the 5' terminal, the activated 5 'terminus is reacted with a marker molecule containing a nucleophilic group, and the nucleotide is cleaved. labeled from the solid phase. This invention also relates to nucleotides labeled at their 5 'terminus using the method described above, wherein the nucleophilic group of the marker molecule moiety is covalently linked directly to the 5' carbon; as well as nucleotide intermediates comprising activated 5 'termini.

Description

METHODS FOR LABELLING OLIGONUCLEOTIDES This invention relates to the covalent coupling of detectable marker molecules into nucleic acid segments referred to as oligonucleotides. More specifically, it relates to 5' end labelling of oligonucleotides wherein each oligonucleotide contains only one marker molecule.
BACKGROUND Labelled oligonucleotides find utility in a number of applications, including DNA sequencing, diagnostic detection or quantitation and forensic science.
Typically, the labelled oligonucleotide is allowed to hybridize or anneal with nucleic acid present in the sample and the presence or absence of label is detected following separation steps. Many mechanisms and schemes have been used to introduce labels into oligonucleotides. For a comprehensive review of these methods see Goodchild, - Bioconjugate Chemistry, 1(3) .165-187 (1990). According to Goodchild, past researchers have labelled oligonucleotides at both internal and terminal locations; by enzymatic and chemical synthetic means; and utilizing a single or many marker molecules per oligonucleotide. Methods involving incorporation of marker moieties at internal locations in the oligonucleotides are generally less preferable due to their less predictable hybridization behavior; end- labelled oligonucleotides are preferred, particularly for automated detection systems. Similarly, methods for incorporating multiple label moieties into an oligonucleotide are less preferred for stoichiometric reasons. Labelling methods which randomly insert radiolabelled or haptenated bases into the oligonucleotide produce a labelled probe which is more difficult to quantitate. The correlation of signal generated to the amount of probe present is not straightforward.
For some applications, it may not be critical that the labelled oligonucleotides are poorly characterized in terms of exact positioning and number of label molecules.
However, for automated diagnostic detection and quantitation, it is desirable that each oligonucleotide have a single marker moiety at an end location. Methods for placing a single marker, or hapten capable of reacting with an antibody or other specific binding member, at a terminal position on an oligonucleotide have been described in the literature.
Most commonly, a linker member containing a primary amine or other nucleophilic group is attached at an available hydroxyl to enable conjugation to one of numerous electrophilic detectable markers. Alternatively, terminal deoxynucleotidyl transferase, ligase and phosphoramidite chemistry have been used to attach direct labels or reactive linkers to oligonucleotides. For example, Ke pe, et al. , Nucleic Acids Research 13(1) :45 (1985) describe biotinylation of the 5' end of synthesized oligonucleotides. In this scheme, an aminoethanol derivative of biotin is condensed with a polymer supported derivatized nucleotide. After the reaction and deprotection, a phosphodiester bond connects the animoethanol-biotin to the nucleoside at the 5' hydroxyl.
Smith, et al.. Nucleic Acids Research 13(7):2399- 2412 (1985) describe a 5' labeling technique utilizing a
5' amino deoxythymidine nucleotide. The 5' amino group is first protected and a phosphoramidite is prepared, which is then used as a final step to add the aminated base to the 5' hydroxyl of the synthesized chain. After cleavage and deprotection, the amino group can be reacted with a number of different electrophilic fluorophores to generate a 5' labelled oligonucleotide.
Coull, et al., Tetrahedron Letters 27(34) .3991-3994 (1986) describe a novel phosphoramidite reagent which introduces a protected primary aliphatic amino group into the 5' terminus of an oligonucleotide under automated synthesis. Following deprotection and cleavage from the support, the amino group can be reacted with a number of electrophilic labels to label the 5' end. Bischoff, et al., Anal. Biochem. 164:336-344 (1987) describe functionalization of the amino groups produced according to Coull's method above. For example, reaction of the 5' primary amine with succinic anhydride gives the
5' carboxylic acid. Similarly, reaction with dithiobis(succinimidylpropionate) followed by treatment with dithioerythritol produced 5' thiolated oligonucleotides. The various functional groups expand the range of possible reactions at the 5' end of these oligonucleotides.
Connolly, Nucleic Acids Research 15(7) :3131-3139 (1987) describes his attempt to prepare protected amino phosphoramidite reagents capable of producing a protected amino group at the 5' position on an oligonucleotide.
Connolly attempts to use different protecting groups selected from dimethoxytrityl and monomethoxytrityl, which can be removed under different conditions than previous protecting groups.
Thuong, et al.. Tetrahedron Letters 29(46) .5905-5908
(1988) describe a method for 5' end labeling a supported oligonucleotide with acridine using phosphoramidite chemistry. Although this method has certain advantages, a separate phosphoramidite reagent must be prepared for each desired label or marker. This adds process steps and expense to the procedure. In addition, the phospho ester bond and the spacer arm of the phosphoramidite reagent remain attached to the oligonucleotide between the sugar residue and the acridine hapten. Each of the above methods have been used to incorporate detectable marker compounds into end positions of oligonucleotides. However, each has drawbacks that make it less than desirable for completely automated synthesis of commercial quantities of oligonucleotides.
For example, reaction of the oligonucleotide with a label moiety after removal from the support requires additional handling. In addition, excess reagent must be used to drive the reaction. This may result in undesirable side reactions and the reaction is usually not completed. Therefore, additional steps of purification (eg. chromatography) are often required, further encumbering the synthesis process and resulting in low yields of labelled oligonucleotides. Accordingly, the present invention seeks to overcome the problems associated with prior methods, and to provide a method for end labelling of oligonucleotides which is amenable to automation and versatile enough to be useful for the addition of any one of many different markers, without the need to prepare specialized reagents for each marker. The invention also eliminates the spacer arms between the 5' carbon of the sugar residue and the marker molecule. SUMMARY OF THE INVENTION
In a first aspect, the invention relates to a method for labeling the 5' end of a nucleotide synthesized on a solid support so as to have a free hydroxyl at the 5' terminal carbon of the nucleotide sugar residue, the method comprising: a. reacting the 5' terminus of the nucleotide sugar residue with a reactant member to produce an activated 5' terminus having a leaving group attached thereto; b. reacting the activated 5' terminus with a marker molecule containing a nucleophilic group to displace the leaving group and covalently attach the marker molecule to the 5' carbon of the nucleotide sugar residue; and c. cleaving the labeled nucleotide from the solid phase.
Preferably, the reactant member is a sulfonyl chloride and the nucleophilic group is selected from the group consisting of amines, thiols and alcohols. The most preferred nucleophilic group is amine. Preferred marker moieties are haptens.
In another aspect, the invention relates to nucleotides labeled at their 5' end by the above process.
Nucleotides according to the invention have the following general structure: B - Sugar-CH - N ' -MM
I 2
Rent wherein B represents a base selected from the group consisting of adenine, cytosine, guanine, thymine, uracil, and analog derivatives thereof; Sugar represents ribose, deoxyribose or analogs thereof; CH. is the methylene group at the 5' terminus of the sugar residue; MM represents a marker molecule; N' represents a nucleophilic group of the marker molecule; and Rem is attached to the sugar residue at its 3' carbon and represents OH, a phosphodiester linkage to a second nucleotide, or a spacer connected to a solid support.
In yet another embodiment the invention relates to intermediates useful for labelling the 5' end of an oligonucleotide. Intermediates have the following general structure: B - - LG wherein B represents a base selected from the group
- consisting of adenine, cytosine, guanine, thymine, uracil, and analog derivatives thereof; Sugar represents ribose, deoxyribose or analogs thereof; CH_ is the methylene group at the 5' terminus of the sugar residue; LG represents a leaving group which can be displaced by a nucleophile; and Rem is attached to the sugar residue at its 3' carbon and represents OH, a phosphodiester linkage to a second nucleotide, or a spacer connected to a solid support. Exemplary leaving groups include aromatic or aliphatic sulfonates, eg. tosylates or esylates.
DETAILED DESCRIPTION As mentioned, the invention is a novel method for labelling the 5' end of an oligonucleotide synthesized on a solid support. Conceptually, the method comprises removing the 5' hydroxyl and activating the 5' carbon with a reactant member capable of exchanging the hydroxyl for a good leaving group; followed by reaction of the activated 5' terminus with a nucleophilic group of a marker molecule.
Many methods for synthesis of oligonucleotides on solid supports have been described in the literature. For example, Goodchild, supra, describes a diester approach; a triester approach; a trivalent phosphate approach, often referred to as the phosphoramidite approach; and, finally, a pentavalent phosphorous approach known as the hydrogen phosphonate approach. It is believed that any of these methods for synthesizing an oligonucleotide may be used in conjunction with the present invention, so long as the 5' hydroxyl group of the sugar of the terminal nucleoside remains available for activation. Presently preferred methods include the phosphoramidite method and the H- phosphonate method. As with the method of synthesis, the particular solid support employed with the invention is not critical.
Essentially the only requirement of the solid support is that it have a functionalized or derivatized group available for reacting with the 3' terminus of a nucleotide. Such solid supports include those which are already derivatized with the first nucleotide, and those which are merely functionalized for the incorporation of the first nucleotide in the chain. Typical solid supports include controlled pore glass (CPG), silica gel and polymer-based resins.
CPG supports are commercially available from Clontech (Palo Alto, CA) and CPG, Inc. (Fairfield, NJ) both with and without the first nucleotide attached. Functionalized solid supports are available with short chain and long chain amino groups as the functional group. The long chain aminated CPG supports are presently preferred.
The reactant member is a reagent capable of exchanging the hydroxyl at the 5' carbon for a "good leaving group". Good leaving groups are well known to those of skill in the art. They are characterized by their electron density which renders them easily displaced by a nucleophile in a substitution reaction generally known as SN2. Reactant members must satisfy two criteria: they must include an "R" group which comprises a "good leaving group"; and they must be sufficiently reactive to displace the 5' hydroxyl and exchange the leaving group in its place. Exemplary and preferred reactant members are described below.
An "activated 5' terminus" refers to the 5r carbon of the sugar residue to which is covalently attached a "good leaving group" instead of the usual hydroxyl group. It is well known to those of skill in the art that good leaving groups comprise the salts of strong acids. Illustrative leaving groups and activated termini are discussed below. A preferred reactant member is an aromatic or aliphatic sulfonyl halide having the general structure:
R - SO. - X where R is an aromatic or aliphatic group and X is a halide, preferably Cl or Br. The term "aromatic" refers to substituted or unsubstituted ring structures generally
known to those skilled in the art to fall into this class, including those compounds which fulfill the Huckel (4n+2) τ~ electrons rule. Particularly preferred are single ring derivatives of benzene having substitutions which enhance the "leaving" ability of the group. Certain substituents in the para-position are generally recognized as fulfilling this function.
Preferred aromatic sulfonyl halide reactant members include p-toluenesulfonyl chloride (toεyl chloride) p- bromobenzenesulfonyl chloride (brosyl chloride) and p- nitrobenzenesulfonyl chloride (nosyl chloride). The R group of the sulfonyl halide reactant members may also be aliphatic. The term "aliphatic" includes groups which may be straight or branched, preferably straight; and ideally no longer than eight backbone atoms total. Alkyl chains having less than about 8 carbons, preferably less than 4, are preferred aliphatic groups for sulfonyl halide reactant members. Both aliphatic and alkyl R groups may include substitutions provided they do not interfere with the criteria of the reactant member. Certain substitutions are useful to enhance the reactant members ability to serve as a leaving group. Exemplary aliphatic reactant members are methanesulfonyl chloride, trifluoromethane sulfonyl chloride, ethanesulfonyl chloride,' 2,2,2 trifluoroethanesulfonyl chloride, propanesulfonyl chloride, and ammonioalkane sulfonyl halides.
Although the recited reactant members have largely been sulfonyl chlorides, it will be recognized by one of ordinary skill in the art that other halides may also be used. For example, it is contemplated that sulfonic acid bromides will function as reactant members in the present invention, when reaction conditions are appropriately modified.
It will also be recognized by those skilled in the art that reactant members equivalent to the sulfonyl halides include any reactant member which bears a suitable "leaving group" and can be made to displace the 5' hydroxyl. It is also possible to utilize a combination of two or more reagents as reactant members. For example, one can convert the 5' hydroxyl to a bromide leaving group using carbontetrahalides and triphenylphosphine.
It will be further recognized that the preferred reactant members, when reacted with a hydroxyl group under appropriate conditions, produce the activated termini shown in Table 1.
Table 1.
Reactant Member Activated 5 ' Termini p-toluenesulfonyl chloride tosylate p-bromobenzensulfonyl ^chloride brosylate p-nitrobenzenesulfonyl chloride nosylate methanesulfonyl chloride mesylate trifluoromethanesulfonyl chloride triflate 2,2,2 trifluoroethane¬ sulfonyl chloride tresylate ammonioalkanesulfonyl halide betalates
The reaction conditions under which aromatic and/or aliphatic sulfonyl halides will react with the 5' hydroxyl to form the activated 5' terminus are generally described in the literature. For example. See March, J. , Advanced Organic Chemistry 3rd Ed (1985) pp310-320. It is within the ability of one of ordinary skill in the art to modify the reaction conditions as necessary for any particular reactant member. Although applicant does not wish to be limited to any particular theory or mechanism of action, it is presumed that the activated 5' terminus undergoes nucleophilic displacement by the nucleophilic group of the marker molecule. It is thus contemplated that other strong leaving groups are the equivalent of the sulfonyl halides discussed above.
The marker molecule employed in the labelling step can be selected from a wide variety of such compounds having nucleophilic groups. The term "marker molecule" is intended to include at least the following 3 classes of molecules:
(1) molecules that are capable of directly providing a detectable signal such as radioactive molecules and chemiluminescent molecules;
(2) molecules which give a detectable signal upon the addition of an external stimulus, such as fluorophores (stimulus is incident radiation); and
(3) molecules, sometimes referred to as "hooks", which are one member of a pair of specific binding partners, such as haptens (bind to antibodies) and biotin (binds to avidin or antibody) .
Of course, many other examples of each type of marker molecule are known to those of skill in the art. Virtually any such molecule may be employed with the present invention, provided it has, or can be modified to contain, a nucleophilic group sterically available for reaction with the activated 5' terminus of the oligonucleotide.
It is presently preferred to utilize marker molecules which fall into the third category; and particularly preferred to utilize small molecular weight haptens. Exemplary haptens are generally known to those skilled in the art and include, without limitation, biotin, iminobiotin, fluorescein, dansyl, acridine, dinitrophenol, dibenzofuran, luminols (eg. N-4-aminobutyl-N-ethyl isoluminol - ABEI). Other useful marker molecules include fluorophores, such as fluorescein and rhodamine; and chemilumiphores, such as acridine and luminols.
Nucleophilic groups useful in the invention include amines, thiols and alcohols, although other nucleophilic groups may be deemed equivalent. Generally, the stronger the nucleophile, the weaker the leaving group may be in terms of its "leaving" ability. Thus, stronger nucleophilic groups would generally be preferred over weaker ones, so that a greater range of leaving groups and reactant members may be employed. However, for reasons of stability and ease of synthesis, the preferred nucleophilic group for the present invention is amines. Primary nucleophilic groups are typically preferred over secondary or tertiary groups. The nucleophilic group found most commonly and most readily available in a plurality of marker moieties is an amino group, preferably a primary amino group.
The reaction conditions under which the nucleophilic group of the marker molecule will react with the activated 5' terminus are well known to those of ordinary skill in the art. Because this reaction is believed to be a nucleophilic displacement, standard textbooks (See for example March, J., supra) give the reaction conditions under which the nucleophilic group will react with the activated 5' terminus to displace the leaving group and covalently bond the marker molecule directly to the 5' carbon of the sugar residue. Variations on these reaction conditions are well within the ability of the routine practitioner. Once the marker molecule has been covalently bonded to the oligonucleotide, the labelled oligonucleotide is cleaved from the solid support. Once again, methods for cleaving the oligonucleotide from the solid support are known to those of ordinary skill in the art. For example, the Applied Biosystems 380B synthesizer generally employs concentrated ammonium hydroxide to separate the oligonucleotide from the support. Other available methods include strong sodium hydroxide and ethanolic 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU - Aldrich Chemical, Milwaukee, WI) . Labelled oligonucleotides prepared according to this invention have utility in a number of diagnostic applications. For example, Whitely, et al., U.S. 4,883,750 describe a diagnostic method in which a diagnostic probe and a contiguous probe are laid down on a target strand and are ligated together. The ligated product is then detected. Incorporation of a marker molecule at the 5 ' end of the probe whose 3' end undergoes ligation would permit rapid detection of the ligated product.
Another diagnostic method is disclosed in EP-A-320 308 and is known as ligase chain reaction (LCR) . In this method, two pairs of probes are utilized, one member of each pair being hybridizable with the other member and with adjacent sections of the target molecule. Using a ligase enzyme, the adjacent probes are covalently bonded together. By repeated cycles of hybridization, ligation and separation, the number of molecules of ligated product increases rapidly if the target is present to serve as a template for adjacent hybridization.
The following examples serve to illustrate the invention further. However, the invention is limited only by the claims which are appended hereto. EXAMPLE 1: Preparation of a 5' Labelled Oligonucleotide Using p-Toluenesulfonyl Chloride
An oligodeoxynucleotide was synthesized using phosphoramidite chemistry on an ABI 380A automated DNA synthesizer according to standard instrument procedure. A 1 /xmole scale protocol, modified to increase reaction time, was used to synthesize a 16 mer. For this experiment the sequence was regularly alternating bases, although it is believed that the specific sequence is immaterial to the invention. The synthesis was programmed with 5' dimethoxytrityl protection off ("DMT-off", see ABI 380A operator manual) while the protected oligonucleotide remained attached to the control pore glass.
The column was removed from the synthesizer. A 10 ml syringe filled with 5 ml of 0.1M solution p-
toluenesulfonyl chloride (Aldrich Chemical, Milwaukee, WI) freshly prepared in dry pyridine was attached to one end of the column via a luer tip. An empty syringe was mounted on the opposite end to receive the eluate. The 0.1M p-toluenesulfonyl chloride solution was carefully passed through the column five times, followed by incubation at 55°C for an additional 24 hours. The excess p-toluenesulfonyl chloride solution was removed and the column was washed with 10 ml of dry acetonitrile. Next, 2 ml of 0.1M N-4-Aminobutyl-N-ethyl isoluminol (ABEI), a hapten and chemilumiphore, in dry dimethylformamide (DMF) was loaded into a 5 ml syringe with luer tip (ABEI, a hapten, and DMF are available from
Aldrich Chemical, Milwaukee, WI). This syringe was mounted on one end of the column. Another syringe was filled with 2 ml of triethylamine solution and mounted on the other end of the column. The solutions were slowly mixed by passing through the column. The mixture was incubated at 55°C for 24 hours, the excess reagent was removed and the column was washed with 20 ml acetonitrile. The 5' labelled DNA was removed from the CPG with the treatment of concentrated NH 4OH for 1 hour under standard
Applied Biosystem Inc. protocols (ABI 380A DNA synthesizer user manual). The 5' labelled oligonucleotide was heated at 55°C overnight, to remove the protecting group from the protected bases. Evaporation of NH40H gave crude 5' labelled oligonucleotides.
EXAMPLE 2: Preparation of a 5' Labelled Oligonucleotide Using Methanesulfonyl Chloride An oligodeoxynucleotide was synthesized using phosphoramidite chemistry on an ABI 380A automated DNA synthesizer according to standard instrument procedure. A 1 /.mole scale protocol, modified to increase the reaction time, was used to synthesize a second 16 mer. For this experiment the sequence was a single base repeated although it is believed that the specific sequence is immaterial to the invention. The synthesis was programmed with 5' dimethoxytrityl protection off ( "DMT- off", see ABI 380A operator manual) while the protected oligonucleotide remained attached to the control pore glass.
The column was removed from the synthesizer. A 10 ml syringe filled with 5 ml of 0.1M solution methanesulfonyl chloride (Aldrich Chemical, Milwaukee, WI) freshly prepared in dry pyridine was attached to one end of the column via a luer tip. An empty syringe was mounted on the opposite end to receive the eluate.
The 0.1M methanesulfonyl chloride solution was carefully passed through the column several times, followed by incubation at 25°C for an additional 24 hours. The excess methanesulfonyl chloride solution was removed and the column was washed with 10 ml of dry acetonitrile.
Next, 2 ml of 0.1M N-4-Aminobutyl-N-ethyl isoluminol
- (ABEI), a hapten and chemilumiphore, in dry dimethylformamide (DMF) was loaded into a 5 ml syringe with luer tip (ABEI, a hapten, and DMF are available from
Aldrich Chemical, Milwaukee, WI). This syringe was mounted on one end of the column. Another syringe was filled with 2 ml of triethylamine solution and mounted on the other end of the column. The solutions were slowly mixed by passing through the column. The mixture was incubated at 25°C for 24 hours, the excess reagent was removed and the column was washed with 20 ml acetonitrile.
The 5' labelled DNA was removed from the CPG with the treatment of concentrated NH 4OH for 1 hour under standard. Applied Biosystem Inc. protocols (ABI 380A DNA synthesizer user manual). The 5' labelled oligonucleotide was heated at 55°C overnight to remove the protecting groups from the protected bases. Evaporation of NH40H gave crude 5' labelled oligonucleotides.
EXAMPLE 3: Evaluation of ABEI Labelled Oligonucleotide
A. By gel separation: The crude 5' ABEI-labelled oligonucleotide from both Examples 1 and 2 were separately redissolved in 0.3M NaOAc followed by 70% ethanol precipitation at 4°C. The DNA pellet was isolated from the mother liquid and evaporated to dryness. The 5' ABEI- labelled DNA was analyzed by electrophoresis in 15% polyacrylamide, 7M urea gel. In both cases, the electrophoretogram showed the hapten labelled DNA migrated as a single blue fluorescent band closer to the origin relative to the unmodified, control oligonucleotide.
B. By UV/VIS spectra: The 5' ABEI-labelled oligonucleotide band and the control oligonucleotide band were extracted from the polyacrylamide gel and assayed with UV/VIS spectroscopy. In both cases, the spectra indicated an absorption peak at 327nm (for ABEI) along with the absorption peak at 260nm (characteristic of DNA).
C. By chemiluminescence: One μL of the 5' ABEI labelled oligonucleotide from Example 1 was added to a TD * (Abbott Laboratories, Abbott Park, IL) cuvette containing 100 μL of distilled water. Then 100 μl> of 0.3 mg/ml Vanadium IV catalyst was added and the cuvette was placed inside a chemiluminometer (Abbott Laboratories, IL; although any commercial chemiluminometer will suffice). 200 μL of 3% hydrogen peroxide in 0.25 N NaOH solution was injected into the cuvette and the emitted light was measured for 5 seconds immediately after the injection. As a control, the experiment was repeated with non- labelled oligonucleotides and no light was emitted. This evaluation procedure can also be repeated with the labelled oligonucleotides of Example 2; or with oligonucleotides labelled with any chemiluminescent marker molecule.
EXAMPLE 4: Preparation of a 5' Labelled Oligonucleotide Using p-Toluenesulfonyl Chloride
Example 1 is repeated except aminomethylfluorescein (AMF: See U.S. Patent 4,510,251, Abbott Laboratories) is used instead of the ABEI reagent. For this example the conditions are the same as in Example 1, but for the marker reagent. Evaluation of this labelled oligonucleotide is done using electrophoresis and/or UV/VIS spectroscopy. The AMF labelled oligonucleotide will have an absorption peak at about 495 nm, in addition to the characteristic DNA peak at 260 nm.
EXAMPLE 5: Preparation of a 5' Labelled Oligonucleotide Using p-Nitrobenzenesulfonyl Chloride
Example 2 is repeated except that 0.1M p- nitrobenzenesulfonyl chloride is used in place of the 0.1M methanesulfonyl chloride. Other conditions and steps remain the same except the reaction times may take a little longer at 25°. Performing the reactions at a higher temperature should decrease the reaction times.
EXAMPLE 6: Preparation of a 5' Labelled Oligonucleotide via a 5r-chloro leaving group
Example 2 is repeated except a solution consisting of carbontetrachloride and triphenylphosphine in acetonitrile, each 0.1M, is used in place of 0.1M methanesulfonyl chloride. The result is a 5'-chloro activated derivative which is reacted with a nucleophilic marker molecule under conditions as in example 2 to label the oligonucleotide. EXAMPLE 7: Preparation of a 5' Labelled Oligonucleotide via a 5'-bromo leaving group
Example 2 is repeated except a solution consisting of carbontetrabromide and triphenylphosphine in acetonitrile, each 0.1M, is used in place of 0.1M methanesulfonyl chloride. The result is a 5'-bromo activated derivative which is reacted with a nucleophilic marker molecule under conditions as in example 2 to label the oligonucleotide.
EXAMPLE 8: Preparation of a 5' Labelled Oligonucleotide via a 5' activation with Mitsunobu reagent
Example 2 is repeated except the syringe at a first end of the column contains a solution (0.1M, 5ml) consisting of triphenylphosphine and 3-hydroxy- dibenzofuran (a hapten) in acetonitrile. The syringe attached to the other end of the column contains a solution (0.1M, 5ml) of diethylazodicarboxylate in acetonitrile. The two solutions are passed alternately through the column to acheive adequate mixing and the column is incubated at 25°C for 24 hours. The excess reagent is removed and the column is washed with acetonitrile (20ml). The result is a dibenzofuran-labeled oligonucleotide (at the 5' end) and removal of the labeled oligonucleotide proceeds as in example 2.

Claims

What is claimed is:
1. A method for labeling the 5' end of a nucleotide synthesized on a solid support so as to have a free hydroxyl at the 5' terminal carbon of the nucleotide sugar residue, the method comprising: a. reacting the 5' terminus of the nucleotide sugar residue with a reactant member to produce an activated 5' terminus having a leaving group attached thereto; b. reacting the activated 5' terminus with a marker molecule containing a nucleophilic group to displace the leaving group and covalently attach the marker molecule to the 5' carbon of the nucleotide sugar residue; and c. cleaving the labeled nucleotide from the solid phase.
2. The method of claim 1 wherein the reactant member of step a is. an aromatic sulfonyl halide.
3. The method of claim 1 wherein the reactant member of step a is an aliphatic sulfonyl halide.
4. The method of claim 3 wherein the reactant member is an alkylsulfonyl chloride.
5. The method of claim 1 wherein the reactant member of step a is a sulfonyl chloride.
6. The method of claim 1 wherein the nucleophilic group of step b is an amine.
7. A nucleotide labeled at its 5' end having the general structure:
B - Sugar-CH2 - N'-MM Rem wherein B represents a base selected from the group consisting of adenine, cytosine, guanine, thymine, uracil, and analog derivatives thereof; Sugar represents ribose, deoxyribose or analogs thereof; CH is the methylene group at the 5' terminus of the sugar residue; MM represents a marker molecule; N' represents a nucleophilic group of the marker molecule; and Rem is attached to the sugar residue at its 3' carbon and represents OH, a phosphodiester linkage to a second nucleotide, or a spacer connected to a solid support.
8. The nucleotide of claim 7 wherein N' is selected from the group consisting of nitrogen, sulfur and oxygen.
9. The nucleotide of claim 7 wherein MM is selected from the group consisting of fluorophores, chemilumiphores and haptens.
10. The nucleotide of claim 7 wherein Rem comprises a phosphodiester linkage to a second nucleotide which, in turn, is connected to one or more additional nucleotides and wherein the 3' terminal nucleotide is attached to a solid support.
11. A nucleotide intermediate having an activated 5' terminus, said intermediate having the following general structure:
B - Sugar-CH_ - LG Rem wherein B represents a base selected from the group consisting of adenine, cytosine, guanine, thymine, uracil, and analog derivatives thereof; Sugar represents ribose, deoxyribose or analogs thereof; CH. is the methylene group at the 5' terminus of the sugar residue; LG represents a leaving group which can be displaced by a nucleophile; and Rem is attached to the sugar residue at its 3' carbon and represents OH, a phosphodiester linkage to a second nucleotide, or a spacer connected to a solid support.
12. The nucleotide intermediate of claim 11 wherein LG has the general structure:
—S02-R wherein R represents an aromatic or aliphatic group.
13. The nucleotide intermediate of claim 12 wherein LG is selected from the group consisting of tosylate, brosylate and nosylate.
14. The nucleotide intermediate of claim 12 wherein R is an aliphatic group comprising a substituted or unsubstituted alkyl chain having less than 4 backbone carbons.
EP92902929A 1990-12-11 1991-12-11 Methods for labelling oligonucleotides Withdrawn EP0562014A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62556690A 1990-12-11 1990-12-11
US625566 1996-03-28

Publications (2)

Publication Number Publication Date
EP0562014A1 true EP0562014A1 (en) 1993-09-29
EP0562014A4 EP0562014A4 (en) 1994-02-23

Family

ID=24506680

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92902929A Withdrawn EP0562014A1 (en) 1990-12-11 1991-12-11 Methods for labelling oligonucleotides

Country Status (6)

Country Link
EP (1) EP0562014A1 (en)
JP (1) JPH05509110A (en)
KR (1) KR930703340A (en)
AU (1) AU9158391A (en)
CA (1) CA2098187A1 (en)
WO (1) WO1992010505A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631361A (en) * 1995-05-22 1997-05-20 Hybridon, Inc. Method of synthesizing radioisotopically labeled oligonucleotides by direct solid-phase 5' phosphitylation
US5919638A (en) * 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
US20050202499A1 (en) 1996-10-31 2005-09-15 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556726A1 (en) * 1983-12-20 1985-06-21 California Inst Of Techn MONOCATENARY OLIGONUCLEOTIDE COMPOSITIONS AND PROCESS FOR THEIR PREPARATION
EP0418076A2 (en) * 1989-09-14 1991-03-20 Tosoh Corporation Oligonucleotide derivative and process for producing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556726A1 (en) * 1983-12-20 1985-06-21 California Inst Of Techn MONOCATENARY OLIGONUCLEOTIDE COMPOSITIONS AND PROCESS FOR THEIR PREPARATION
EP0418076A2 (en) * 1989-09-14 1991-03-20 Tosoh Corporation Oligonucleotide derivative and process for producing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 112, no. 15, 9 April 1990, Columbus, Ohio, US; abstract no. 139718q, HERDEWIJN P ET AL 'Synthesis and biological activity of the mono- and diamino analogs of 2'-deoxyadenosine, cordycepin, 9-(3-deoxy-beta-D-threo-pentof uanosyl)adenine (a structural component of agrocin 84) and 9-(2-deoxy-beta-D-threo-pe ntofuranosyl)adenine' column 2 ; & NULEOSIDES NUCLEOTIDES vol. 8, no. 7 , 1989 pages 1231 - 1257 *
NUCLEIC ACIDS RESEARCH vol. 15, no. 15 , 1987 , OXFORD, UK pages 6181 - 6196 SPROAT B.S. ET AL 'The synthesis of protected 5'-amino-2',5'-dideoxyribonucleo side-3'-O-phosphoramidites; applications of 5'-amino-oligodeoxyribonucleotides' *
See also references of WO9210505A1 *

Also Published As

Publication number Publication date
AU9158391A (en) 1992-07-08
CA2098187A1 (en) 1992-06-11
EP0562014A4 (en) 1994-02-23
WO1992010505A1 (en) 1992-06-25
JPH05509110A (en) 1993-12-16
KR930703340A (en) 1993-11-29

Similar Documents

Publication Publication Date Title
US5696251A (en) Non-nucleotide linking reagents for nucleotide probes
US6031091A (en) Non-nucleotide linking reagents for nucleotide probes
KR970005898B1 (en) Non-nucleotide linking reagents for nucleotide rpobes
EP0543913B1 (en) Oligo(alpha-arabinofuranosyl nucleotides) and alpha-arabinofuranosyl precursors thereof
US5430138A (en) Hydroxyl-protecting groups attached to cytidine nucleotide compounds which are orthogonally removable
US6117986A (en) Pyrimidines linked to a quencher
KR101032008B1 (en) Polynucleotide labelling reagent
US20050027116A1 (en) Solid phase synthesis
US7858772B2 (en) Compounds and methods for synthesis and purification of oligonucleotides
EP0424819B1 (en) Reversible modification of biological compounds for detection, separation and purification thereof
CA2443122A1 (en) Mobility-modified nucleobase polymers and methods of using same
JPH07233188A (en) New nucleosidephosphoramidite and its preparation
JPH06145192A (en) Synthesis of amino-derived oligonucleotide
WO2008037568A2 (en) Reversible terminators for efficient sequencing by synthesis
WO1989002896A1 (en) Acridinium ester labelling and purification of nucleotide probes
AU2006316903B2 (en) Polynucleotide labelling reagent
EP0562014A1 (en) Methods for labelling oligonucleotides
US7098326B2 (en) Methods for the integrated synthesis and purification of oligonucleotides
US6664058B2 (en) Base analogues
US20030118999A1 (en) Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof
EP0310312A2 (en) Non-nucleotide reagents for substituting termini of oligonucleotides
EP2170924B1 (en) 5-bromo-2'-deoxy-uridine labeled nucleotide triphosphates and nucleic acid probes and methods of making and using the same
US7276598B2 (en) Phosphorylation reagents for improved processes to convert terminal hydroxyl groups of oligonucleotides into phosphate monoesters
JP2005073605A (en) Nucleotide-labeled reagent and oligonucleotide derivative in which the same reagent is introduced
AU2554288A (en) Acridinium ester labelling and purification of nucleotide probes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RHK1 Main classification (correction)

Ipc: C07H 21/00

A4 Supplementary search report drawn up and despatched

Effective date: 19940104

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950701